Cargando…

Role of antibody-based therapy in indolent non-Hodgkin's lymphoma

Monoclonal antibodies (mAb) for indolent non-Hodgkin's lymphoma (iNHL) including follicular and marginal zone lymphomas was a key therapeutic development that changed the natural history of these diseases. Rituximab, a chimeric anti-CD20 mAb, was the first immunotherapy ever used in cancer, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Willard, Patrick, McKay, John, Yazbeck, Victor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569585/ https://www.ncbi.nlm.nih.gov/pubmed/34765437 http://dx.doi.org/10.1016/j.lrr.2021.100275

Ejemplares similares

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
por: Aldoss, Ibrahim T, et al.
Publicado: (2009)

Immunotherapy in indolent Non-Hodgkin's Lymphoma
por: Amhaz, Ghid, et al.
Publicado: (2022)

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
por: Leslie, Lori A.
Publicado: (2021)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas
por: Minson, Adrian, et al.
Publicado: (2022)

Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
por: Tageja, Nishant
Publicado: (2011)

Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
por: Weide, Rudolf
Publicado: (2008)

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas
por: Gunnellini, Marco, et al.
Publicado: (2012)

The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas
por: Artemaki, Pinelopi I., et al.
Publicado: (2021)

Increased plasma endostatin and GDF15 in indolent non-Hodgkin lymphoma
por: Hidman, Josefin, et al.
Publicado: (2023)

Factors Impacting Treatment Decision Making in Older Adults With Indolent Non-Hodgkin Lymphoma
por: Trevino, Kelly, et al.
Publicado: (2021)

Systemic Relapse in a Young Adult Patient with Primary CNS Diffuse Large B-Cell Lymphoma
por: Khorasanchi, Adam, et al.
Publicado: (2022)

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma
por: Andorsky, David J., et al.
Publicado: (2018)

Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin’s lymphoma: a monocenter analysis
por: Hadi, I., et al.
Publicado: (2021)

Comparison of CT, PET, and PET/CT for Staging of Patients with Indolent Non-Hodgkin’s Lymphoma
por: Fueger, Barbara J., et al.
Publicado: (2009)

Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential
por: Barrientos, Jacqueline C
Publicado: (2016)

An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma
por: Darwish, Mona, et al.
Publicado: (2014)

Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress
por: Lin, Yi, et al.
Publicado: (2014)

Long-term complete responses after (131)I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma
por: Buchegger, F, et al.
Publicado: (2006)

Autoantibody-Mediated Sensory Polyneuropathy Associated with Indolent B-Cell Non-Hodgkin's Lymphoma: A Report of Two Cases
por: Stübgen, Joerg-Patrick
Publicado: (2015)

Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy
por: Grover, Natalie S., et al.
Publicado: (2015)

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
por: Barrington, Sally F., et al.
Publicado: (2017)

Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
por: Castaneda-Puglianini, Omar, et al.
Publicado: (2021)

Surgery for Non-Hodgkin’s Lymphoma
por: Weledji, Elroy Patrick, et al.
Publicado: (2015)

Repeated courses of low‐dose 2 × 2 Gy radiation therapy in patients with indolent B‐cell non‐Hodgkin lymphomas
por: Saleh, Khalil, et al.
Publicado: (2020)

Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis
por: Yuan, Ting, et al.
Publicado: (2017)

Toxic Encephalopathy After Relapsed Indolent Non-Hodgkin’s Lymphoma Following Abrupt Discontinuation of Idelalisib (ZYDELIG®)
por: Shenouda, Mina, et al.
Publicado: (2019)

Association of germline TYK2 variation with lung cancer and non‐Hodgkin lymphoma risk
por: Yarmolinsky, James, et al.
Publicado: (2022)

Immune Response to Combination Therapy for Non-Hodgkin Lymphomas
por: Weiss, Robert F., et al.
Publicado: (2013)

Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis
por: Tang, Xiao, et al.
Publicado: (2022)

Proton therapy in the management of non-Hodgkin lymphoma
por: Sachsman, Suzanne, et al.
Publicado: (2015)

Parametric Model of Combination Therapy for Non-Hodgkin Lymphoma
por: Weiss, Robert F., et al.
Publicado: (2012)

The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use
por: Tavarozzi, Rita, et al.
Publicado: (2022)

Non-Hodgkin's Lymphomas
por: Proctor, S.J.
Publicado: (1994)

Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives
por: Motta, Giulia, et al.
Publicado: (2010)

Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice
por: Becker, M., et al.
Publicado: (2015)

Genetic susceptibility to therapy-related leukemia after Hodgkin lymphoma or non-Hodgkin lymphoma: role of drug metabolism, apoptosis and DNA repair
por: Ding, Y, et al.
Publicado: (2012)

Peripheral T Cell Non-Hodgkin's Lymphoma following Treatment of Hodgkin's Lymphoma
por: Chang, Sun Hee, et al.
Publicado: (2015)

Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells
por: Fucà, Giovanni, et al.
Publicado: (2021)

Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-analysis
por: Banerjee, Titas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2nmfqti16p54abja6cp1grvk5n